Why is Twist Bioscience stock sliding today?
Twist Bioscience (TWST) stock fell 7.1% in pre-market trading after reporting a wider-than-expected Q4 2026 loss of $0.44 per share, despite revenue slightly above estimates at $124.8 million. Analysts had anticipated a loss of $0.38 per share on revenue of $123.6 million. The miss, combined with a bearish report, high short interest, and a declining market, contributed to the decline. The NASDAQ and S&P 500 also fell 0.9% and 0.4%, respectively.
How this was made
The 30-second read
Why it matters
The earnings miss validates concerns about profitability, likely prompting short covering and further downside.
Market read
The earnings surprise drives a notable pre‑market sell‑off, reinforcing bearish sentiment in the biotech growth segment.
What to watch
Upcoming pipeline milestones or partnership announcements could offset the earnings disappointment.
Background
Twist Bioscience is a high‑beta genomics tool maker with a premium valuation; recent short‑seller report heightened scrutiny.
Ticker impact
Twist Bioscience reported Q4 2026 earnings with a per‑share loss ~16.7% worse than consensus, causing a 7.1% pre‑market decline.
downward pressure as investors price in weaker profitability and high valuation premium.
The surprise loss and elevated short interest suggest continued selling pressure in the near term.
Market effects
The miss adds to pressure on the life‑science tools and genomics sector, which is already facing scrutiny over AI‑driven demand narratives.
NASDAQ’s broader decline amplifies the sell‑off in high‑beta growth stocks like Twist.
Limited to U.S. biotech and growth‑oriented investors; no immediate global macro effect.
Counterpoint
If the short‑seller report was overblown, the stock could rebound on a potential valuation correction.
Key entities
- companyTwist Bioscience Corp
US‑listed genomics tool manufacturer (ticker TWST).
